Related Experiment Video

Updated: Apr 20, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

8.0K

Targeting protein kinase C in sarcoma

J Martin-Liberal1, A J Cameron2, J Claus3

  • 1Sarcoma Unit, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK.

Biochimica Et Biophysica Acta
|December 3, 2014
PubMed

Insights

Protein kinase C (PKC) is a key regulator of cell processes, often dysregulated in cancers. Targeting PKC with small molecules shows promise for developing novel oncology therapeutics, particularly for sarcoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Protein kinase C (PKC) is a family of serine/threonine tyrosine kinases.
  • PKC regulates critical cellular functions like division, proliferation, and survival.
  • Aberrant PKC signaling is implicated in various human cancers, making it a therapeutic target.

Purpose of the Study:

  • To provide a structure-function overview of the PKC family.
  • To explore the rationale for targeting PKC in sarcoma treatment.
  • To review the current status of PKC inhibition in clinical oncology.

Main Methods:

  • Literature review of PKC family structure and function.
  • Analysis of PKC signaling in cancer models, specifically sarcoma.
  • Survey of ongoing clinical trials and therapeutic strategies involving PKC inhibitors.

Main Results:

  • PKC kinases play a vital role in cellular processes relevant to cancer.
  • Sarcomas, often chemoresistant, present an opportunity for novel targeted therapies.
  • Several small molecule inhibitors targeting PKC are under investigation for oncology applications.

Conclusions:

  • Understanding PKC structure-function is crucial for targeted drug development.
  • PKC inhibition is a promising therapeutic strategy for sarcoma.
  • The clinical landscape of PKC inhibitors in oncology is evolving, with ongoing research.
Keywords:
KinasesProtein kinase CSarcomaTherapeutics

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.9K
Assaying Protein Kinase Activity with Radiolabeled ATP08:05

Assaying Protein Kinase Activity with Radiolabeled ATP

Published on: May 26, 2017

19.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.8K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.5K